Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/27644
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMartín-Martín, Lourdes-
dc.contributor.authorAlmeida, Julia-
dc.contributor.authorPomares, Helena-
dc.contributor.authorGonzález-Barca, Eva-
dc.contributor.authorBravo Barahona, Pilar-
dc.contributor.authorGiménez, Teresa-
dc.contributor.authorHeras, Cecilia-
dc.contributor.authorQueizán, José-Antonio-
dc.contributor.authorPérez-Ceballos, Elena-
dc.contributor.authorMartínez, Violeta-
dc.contributor.authorAlonso, Natalia-
dc.contributor.authorCalvo, Carlota-
dc.contributor.authorÁlvarez, Rodolfo-
dc.contributor.authorCaballero, María Dolores-
dc.contributor.authorOrfao, Alberto-
dc.date.accessioned2019-06-28T15:20:38Z-
dc.date.available2019-06-28T15:20:38Z-
dc.date.issued2016-03-01-
dc.identifier.citationOncotarget.2016 Mar;(7)9:10174-81-
dc.identifier.urihttps://hdl.handle.net/20.500.12530/27644-
dc.description.abstractBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive myeloid neoplasm which shows a high rate of central nervous system (CNS) recurrence and overall survival (OS) of <1 year. Despite this, screening for CNS involvement is not routinely performed at diagnosis and intrathecal (IT) prophylaxis is not regularly administered in BPDCN. Here, we prospectively evaluated 13 consecutive BPDCN patients for the presence of CNS involvement by flow cytometry. Despite none of the patients presented with neurological symptoms, occult CNS involvement was detected in 6/10 cases evaluated at diagnosis and 3/3 studied at relapse/progression. BPDCN patients evaluated at diagnosis received IT treatment -either CNS prophylaxis (n = 4) or active therapy (n = 6)- and all but one remain alive (median follow-up of 20 months). In contrast, all three patients assessed at relapse/progression died. The potential benefit of IT treatment administered early at diagnosis on OS and CNS recurrence-free survival of BPDCN was further confirmed in a retrospective cohort of another 23 BPDCN patients. Our results show that BPDCN patients studied at diagnosis frequently display occult CNS involvement; moreover, they also indicate that treatment of occult CNS disease might lead to a dramatically improved outcome of BPDCN.-
dc.language.isoeng-
dc.rightsopenAccess-
dc.subjectALL therapy-
dc.subjectblastic plasmacytoid dendritic cell neoplasm-
dc.subjectcentral nervous system-
dc.subjectflow cytometry-
dc.subjectintrathecal prophylaxis-
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshCentral Nervous System-
dc.subject.meshCentral Nervous System Neoplasms-
dc.subject.meshChild-
dc.subject.meshDendritic Cells-
dc.subject.meshFemale-
dc.subject.meshHematologic Neoplasms-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Recurrence, Local-
dc.subject.meshProspective Studies-
dc.subject.meshRetrospective Studies-
dc.subject.meshTreatment Outcome-
dc.subject.meshYoung Adult-
dc.titleBlastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy.-
dc.typeArtículo-
dc.identifier.pubmedID26840087-
dc.format.volume7-
dc.format.page10174-81-
dc.identifier.e-issn1949-2553-
dc.identifier.journalOncotarget-
dc.contributor.authoraffiliationHospital Universitario de Fuenlabrada. Servicio de Hematología-
dc.identifier.doi10.18632/oncotarget.7101-
dc.format.number9-
dc.subject.decsNeoplasias del Sistema Nervioso Central-
dc.subject.decsRecurrencia Local de Neoplasia-
dc.subject.decsNeoplasias Hematológicas-
dc.subject.decsCélulas Dendríticas-
dc.identifier.pmcPMC4891111-
dc.pubmedtypeJournal Article-
dc.pubmedtypeResearch Support, Non-U.S. Gov't-
Appears in Collections:Hospitales > H. U. Infanta Leonor > Artículos
Hospitales > H. U. de Fuenlabrada > Artículos

Files in This Item:
File Description SizeFormat 
PMC4891111.pdf1.25 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.